Complementary and alternative medicine use by patients enrolled onto phase I clinical trials

被引:87
作者
Dy, GK
Bekele, L
Hanson, LJ
Furth, A
Mandrekar, S
Sloan, JA
Adjei, AA
机构
[1] Mayo Clin, Div Med Oncol, Dept Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Biostat, Coll Med, Rochester, MN 55905 USA
关键词
D O I
10.1200/JCO.2004.03.121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To describe the prevalence, clinical characteristics, and pattern of use of complementary and alternative medicine (CAM) in patients enrolled onto phase I trials. Patients and Methods Questionnaires were administered to 108 patients with advanced malignancies enrolled onto phase I chemotherapy trials at the Mayo Clinic Comprehensive Cancer Center (Rochester, MN). CAM was classified into two modalities, pharmacologic and nonpharmacologic. Clinical and demographic data, including age, sex, and prior cancer treatment, were subsequently obtained from patient charts and examined for any correlation with CAM use, using chi(2) analysis. Results One hundred two survey forms were returned. Among respondents, 88.2% (90 of 102) had used at least one CAM modality; 93.3% (84 of 90) and 53.3% (48 of 90) had used pharmacologic and nonpharmacologic CAM, respectively; and 46.7% (42 of 90) used both modalities. Vitamin and mineral preparations constituted 89.3% (75 of 84) of all pharmacologic CAM used. Intake was highest for vitamins E (48.8% [41 of 84]) and C (38.1% [32 of 84]), and 71.4% (60 of 84) of respondents took nonvitamin/mineral agents. Green tea (29.8% [25 of 84]), echinacea (13.1% [11 of 84]), and essiac (9.5% [8 of 84]) were the most popular. Prayer and spiritual practices were the most commonly used nonpharmacologic CAM, accounting for 52.1% (25 of 48). Chiropractors, the most frequently visited nontraditional medicine practitioners, were consulted by only 10% (9 of 90) of those who practiced CAM. Both CAM modalities were used more frequently by women (53.5% [23 of 43]) than men (40.4% [19 of 47]). Conclusion CAM use is common among patients in phase I trials and should be ascertained by investigators, because some of the agents used may interact with investigational agents and affect adverse effects and/or efficacy. (C) 2004 by American Society of Clinical Oncology
引用
收藏
页码:4810 / 4815
页数:6
相关论文
共 43 条
[1]  
Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
[2]  
BLUM JR, 1961, ANN MATH STAT, V32, P485, DOI 10.1214/aoms/1177705055
[3]   Use of complementary/alternative medicine by breast cancer survivors in Ontario: Prevalence and perceptions [J].
Boon, H ;
Stewart, M ;
Kennard, MA ;
Gray, P ;
Sawka, C ;
Brown, JB ;
McWilliam, C ;
Gavin, A ;
Baron, RA ;
Aaron, D ;
Haines-Kamka, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) :2515-2521
[4]   An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures [J].
Budzinski, JW ;
Foster, BC ;
Vandenhoek, S ;
Arnason, JT .
PHYTOMEDICINE, 2000, 7 (04) :273-282
[5]   Discussing complementary therapies with cancer patients: What should we be talking about? [J].
Burstein, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (13) :2501-2504
[6]   Use of alternative medicine by women with early-stage breast cancer [J].
Burstein, HJ ;
Gelber, S ;
Guadagnoli, E ;
Weeks, JC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (22) :1733-1739
[7]   CONTEMPORARY UNORTHODOX TREATMENTS IN CANCER MEDICINE - A STUDY OF PATIENTS, TREATMENTS, AND PRACTITIONERS [J].
CASSILETH, BR ;
LUSK, EJ ;
STROUSE, TB ;
BODENHEIMER, BJ .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (01) :105-112
[8]  
Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986
[9]  
Coeugniet E G, 1987, Onkologie, V10, P27
[10]   Novel pharmacological agents in clinical development for solid tumours [J].
Dy, GK ;
Haluska, P ;
Adjei, AA .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (12) :2059-2088